Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.4 (
deaminase
)
5,113
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The nucleotide sequences of genes cpl7 and cpl9 of the Streptococcus pneumoniae bacteriophages Cp-7 and Cp-9, encoding the muramidases
CPL
-7 and
CPL
-9, respectively, have been determined. The N-terminal domains of
CPL
-7 and
CPL
-9 were virtually identical to that previously reported for the
CPL
-1 muramidase. The C-terminal domain of the
CPL
-7 muramidase, however, was different from those of the host
amidase
and the phage Cp-1 and Cp-9 lysozymes. Whereas all enzymes studied are characterized by repeated sequences at their C termini, the repeat-unit lengths are 20 amino acids (aa) in
CPL
-1,
CPL
-9 and in the host
amidase
, but 48 aa in
CPL
-7. Six repeated sequences represent the C-terminal domains of
CPL
-1,
CPL
-9 and the host
amidase
, and 2.8 perfect tandem repetitions that of
CPL
-7. The peculiar characteristics of the structure of
CPL
-7 muramidase correlate with its biochemical and biological properties. Whereas
CPL
-1,
CPL
-9 and the pneumococcal
amidase
strictly depend on the presence of choline-containing cell walls for activity,
CPL
-7 is able to degrade cell walls containing either choline or ethanolamine. These results support the previously postulated role for the C-terminal domain of these lytic enzymes in substrate recognition and provide further experimental evidence supporting the notion that the proteins have evolved by an exchange of modular units.
...
PMID:Modular organization of the lytic enzymes of Streptococcus pneumoniae and its bacteriophages. 231 37